Aplastic Anemia Foundation Backs New Treatment
According to recent reports, the Aplastic Anemia & MDS International Foundation has awarded Vidaza a positive opinion for human use. The award was reportedly given to the European Committee for Medical Products for Human use (CHMP). The news is very pleasing and hopeful to patients who aren’t eligible to receive stem cell transplants to treat their illnesses.
The CHMP’s positive opinion for the use of Vidaza for human treatment is reportedly based upon data gathered from the AZA-001 trial, which demonstrated a higher survival rate for those with severe cases of myelodysplastic syndromes (MDS) and aplastic anemia. The Aplastic Anemia & MDS International Foundation is supposedly going to forward their approval to the European Commission. In doing so, the recommendation of Vidaza by the CHMP will be enabled to receive final marketing approval.
Reasoning Behind the Approval
“We are excited by Vidaza’s positive CHMP opinion because there are few treatment options for patients in Europe with this disease,” explains John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation, “Vidaza not only extends patients’ lives, but also improves their quality of life. We are hopeful that Vidaza will receive marketing approval shortly and quickly be available for patients across Europe.”
Aplastic anemia is a rare condition where the bone marrow doesn’t produce sufficient new cells in order to replenish the blood cells. The aplastic Anemia & MDS International Foundation is committed to serving as a dependable resource for patient assistance and support. The organization provides patients and families with the latest medical information and funds to research and find cures for aplastic anemia and other related illnesses.
